PTC Therapeutics Reports Negative EMA's CHMP Completed Review Of Proposed Indication Extension For Translarna; Co. Was Informed EMA Reps That EPAR Will Be Updated To Clarify Patients Who Start Translarna Not Required To Discontinue Treatment